Figure 6.

Intra-pulmonary delivery of sh-lincRNAp21 in pristane-induced model of DAH. (A) Pulmonary hemorrhagic frequencies of sh-luciferase- and sh-lincRNAp21-treated mice on day 14 (left panel). Representative gross and histopathology findings in the lungs with no, partial and complete hemorrhage (right panel). (B) Hb, Hct and RBC of sh-luciferase- and sh-lincRNAp21-treated mice on day 14. (C) LincRNA-p21 expression levels in the lungs (left panel) and spleen (right panel) from sh-luciferase- and sh-lincRNAp21-treated mice on day 14. Bax expression levels in the lungs (middle panel) from sh-luciferase- and sh-lincRNAp21-treated mice on day 14. (D) Representative TUNNEL staining in lung tissues from sh-luciferase- and sh-lincRNAp21-treated mice (left panel, ×400). Bars shown on photomicrographs corresponding to 20 μm. Numbers of TUNEL-positive cells (right panel), as determined by averaging the number from 3 fields (×400) of the highest density of positively stained cells in each section. Relative abundance of a measured gene expression was normalized by GAPDH gene from each sample. The average levels of lung and spleen tissues from sh-luciferase-treated mice on day 14 were determined as 100%. Values are the mean ± SEM with 16 mice per group in (A,B), and 8 mice per group in (C,D). All of the in vivo results in Figure 6 were representative of two independent experiments with similar findings. * p < 0.05, ** p < 0.01, *** p < 0.001.